Ziwig Wins BFM Business Award of the Year for therapeutic breakthrough for ENDOTEST®
On the second edition of the Check Up Health Awards, BFM Business honored yesterday the health actors, rewarding the initiatives which marked the year. Among the prizes awarded by the jury composed of nine experts and health professionals, the prize for the therapeutic advance of the year was awarded to Ziwig for its endometriosis diagnostic test.
Paris, May 18, 2022 – On Tuesday, May 17, 2022, French start-up ZIWIG received the BFM Business Award for Therapeutic Advancement of the Year for ENDOTEST®.
ENDOTEST® is a diagnostic test for endometriosis based on the exploration of human micro RNA present in saliva. ENDOTEST® uses two cutting-edge technologies: Next Generation Sequencing and artificial intelligence. Its reliability, close to 100%, is superior to that of all currently available diagnostic tools.
Today, women suffering from endometriosis are subjected to a long period of medical wandering (8 years on average). Thanks to a simple saliva sample that is to be sent to a medical analysis laboratory, ENDOTEST® will now allow them to know, within a few days, whether or not they have endometriosis.
ENDOTEST® is CE-marked, which allows it to be distributed in all European countries. It will be available in Switzerland from June 1, 2022. Applications for reimbursement have been submitted to the various competent national authorities, in order to allow all women to have access to it, regardless of their socio-economic status.
Ziwig’s goal is to provide women with suspected endometriosis with access to a reliable, rapid and non-invasive diagnosis and the possibility of early care to improve their quality of life.
Yahya El Mir, president of Ziwig
and Marie-Agnès Caderby, head of the Ile-de-France region of the Endomind association